Leveraging Technology to Cut Through the REMS Confusion
The Risk Evaluation and Mitigation Strategies (REMS) program has taken center stage recently as the Food and Drug Administration (FDA), pharmacies and healthcare providers seek ways to improve and streamline its administration. Created in 2007 as part of the FDA Amendments Act, REMS was designed to ensure that the benefits of a drug or biological product outweigh its risks, as well as for post-marketing surveillance of medication safety. While providers agree with these goals, many are also concerned with issues they believe are preventing REMS from achieving its objectives.
You may also like:
As the U.S. Department of Health and Human Services (HHS) focuses its attention on drug pricing, a pharmacy advocacy group is urging HHS leadership not to ignore the issues presented by direct and indirect remuneration (DIR) fe...
Patient engagement is defined differently by various clinicians, caregivers, health plans, and other providers. And healthcare organizations can have vastly divergent engagement goals. But one thing the majority of the healthca...
A recent study sought to quantify the burden of opioid-related deaths in the United States and compare this burden over time and by age and sex.
Stay in the Know
Sign up to start receiving notifications via email of our upcoming webinars!